Masavibart
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2640223-84-1
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
製品説明
Isotype
Human IgG1 lambda
Recommend Isotype Controls
Species Reactivity
Virus
IC50 & Target
SARS-CoV-2
体外実験
Masavibart (ZRC3308-A7; 0-5×105 ng/mL) shows virus neutralizing ability in VeroE6/Vero CCL81 (SARS-CoV-2 infection model) cells, when in combination with ZRC3308-B10 (ratio 1:1)[1].
Masavibart neutralizes SARS-CoV-2 variants B.1.1.7, B.1.351, B.1.617.2, and B.1.617.2 AY.1 in vitro, when in combination with ZRC3308-B10 (ratio 1:1) [1].
Masavibart binds to the RBD of SARS-CoV-2 S1 protein[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:VeroE6/Vero CCL81 cells (SARS-CoV-2 infection model)
-
Concentration:0-5×105 ng/mL (in combination with ZRC3308-B10)
-
Incubation Time:72 h
-
Result:Showed potent neutralization activity with an IC50 of 0.1527 ng/mL.
体内実験
Masavibart (0.5, 2.5, 25 mg/kg; i.p.; single) shows the serum levels remaines constant without much reduction for up to 7 days, in syrian hamster [1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female syrian hamster (7 to 10-week-old; SARS-CoV-2 infection model)[1].
-
Dosage:0.5, 2.5, 25 mg/kg
-
Administration:Intraperitoneal injection; 48 h prior to the SARS-CoV-2 infection
-
Result:Prevented SARS-CoV-2 infection when in combination with ZRC3308-B10.
遺伝子ID
アクセッション番号
YP_009724390.1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 lambda
アプリケーション
ELISA, FACS, Functional assay
化学情報
-
CAS 番号 2640223-84-1
-
SMILES
[Masavibart]
-
別名
ZRC3308-A7
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Masavibart 関連分類
HY-145642 関連分類
Powered by Bioz